Development of Marine Antihyperlipidemic Drug

Eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) are important polyunsaturated fatty acids. They have many beneficial properties for human health, such as the prevention of circulatory diseases such as thrombosis and arteriosclerosis, protection of cognitive function during aging, and infant development. The overall capacity of the human organism to synthesize these fatty acids is relatively low, so they must be ingested from dietary sources. The most important source is fish oil. Lower marine organisms such as microalgae are playing an increasingly important role as PUFA producers due to the disturbing taste and odor of fish-derived PUFA products and the continued depletion of fish stocks worldwide. Photoautotrophic microalgae like Nannochloropsis can be cultured on an industrial scale and accumulate large cell clumps in the form of lipids. Screening microbial PUFA synthesis genes from metagenomic libraries allows the related genes to be cloned and expressed in a suitable host. At CD BioSciences, we are dedicated to pushing the boundaries of marine drug discovery and leveraging our expertise to develop innovative antihyperlipidemic drugs for the betterment of human health.

Fig 1. Structures of eicosapentaenoic acid (A) and docosahexaenoic acid (B). (Lindequist U, 2016)

Our Services

Our ocean-derived drug discovery platform enables us to rapidly develop compound candidates with balanced properties and strong intellectual property protection. We handle any type of compound and all our work is done in-house to ensure quality and speed.

• Aquaculture/Cultivation of Marine Organisms
  Our scientists grow macroalgae and microalgae, certain types of invertebrate cells, marine fungi and several species of marine bacteria in bioreactors
• Genetic Engineering
  We attempt to apply genetic engineering techniques to isolate and express genes from organisms that cannot be cultured. We try to do it on an industrial scale for marine drugs.
• Synthesis/Semi-synthesis/Modification of Marine-derived Compounds
  In most cases, the original natural compound is the "lead structure" and it is not necessary to generate the entire structure. We modify natural compounds to increase their structural variability and improve product properties.
• Structure-Activity Relationship (SAR) Studies of Marine-derived Compounds
  CD BioSciences utilizes SAR studies to elucidate the relationships between the structure of marine compounds and their antihyperlipidemic activity.
• Antihyperlipidemic Activity Research
  We study the antihyperlipidemic effects of marine-derived compounds by establishing animal disease models.

Our Advantages

• Access to novel compounds
  By harnessing the vast potential of marine organisms, CD BioSciences provides clients with access to a diverse pool of chemically unique and biologically active compounds.
• Improved efficacy and safety
  Marine antihyperlipidemic drugs offer the potential for improved efficacy and safety profiles, mitigating the risks.
• Source of inspiration
  Marine organisms offer a vast source of inspiration for the development of new therapeutic agents with unique structures and mechanisms of action.
• Sustainable and environmentally friendly
  The development of marine antihyperlipidemic drugs aligns with the principles of sustainability and environmental stewardship, promoting the conservation of marine resources.

CD BioSciences is a professional service provider for the marine biology industry. Our marine antihyperlipidemic drug development services can ensure that the most suitable methods and techniques are selected for your project. We provide our customers with the most precise ingredient data and highly informed process expertise. Our team of biomass experts plays a key role in the formulation, optimization and commercial evaluation of biomass value-added processes in industry and academia. If necessary, please feel free to contact us.

Reference

• Lindequist U. Marine-derived pharmaceuticals–challenges and opportunities[J]. Biomolecules & therapeutics, 2016, 24(6): 561.

Please kindly note that our services can only be used to support research purposes (Not for clinical use).